Targacept, Inc.

📍 Winston-Salem, United States🗓 Founded 1997👥 30 employees💰 Last funded Aug 2000
Biotechnology Research🌐 targacept.com
Website LinkedIn
Targacept is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, unique proteins that regulate vital biological functions that are impaired in various disease states. Targacept’s clinical pipeline includes multiple Phase 2 product candidates, all representing first-in-class opportunities. Targacept leverages its scientific leadership and diverse pipeline to attract significant collaborations with global pharmaceutical companies. For more information, please visit www.targacept.com.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
1997
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
1
Frequently asked questions
Who invested in Targacept, Inc.?
Targacept, Inc. has 1 investors on record on gritt.io, 1 mid-stage.
When did Targacept, Inc. last raise funding?
The most recent investment in Targacept, Inc. recorded on gritt.io was in August 2000.
When was Targacept, Inc. founded?
Targacept, Inc. was founded in 1997.
What industry is Targacept, Inc. in?
Targacept, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Targacept, Inc. based?
Targacept, Inc. is headquartered in Winston-Salem, United States.